PCNA and triple-negative breast carcinoma: In particular Monensin demonstrated to reduce triple-negative breast cancer (TNBC) development without displaying anti-proliferative effect on malignant tissues, evident by no significant changes in Proliferating Cell Nuclear Antigen (PCNA) and Ki-67 expression (Fiorilla et al., 2025).